3:38 PM
 | 
Nov 10, 2017
 |  BioCentury  |  Finance

Making introductions

How Newton hopes to facilitate deals between Europe, Japan with €200 million fund

Newcomer Newton Biocapital is raising a €200 million ($231.7 million) fund to invest in early stage healthcare companies in Europe and Japan and facilitate partnerships and M&A between the two regions.

Newton, which was established in April, has offices in Brussels and Tokyo and is led by established life sciences investors Alain Parthoens and Goro Takeda.

Parthoens is co-founder and managing partner at Vesalius Biocapital Partners and previously served as an investment director at ING.

Takeda is a venture partner...

Read the full 383 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >